MUMBAI (Reuters) - Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, said it will buy some established brands of Belgian drugmaker UCB SA in India, Nepal, Sri Lanka and Maldives for 8 billion rupees ($128.38 million).
The deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement to the Bombay Stock Exchange.
The acquired business generated full-year 2014 revenue of about 1.5 billion rupees, Dr Reddy's said.
Reuters reported last month that Dr Reddy's was in talks with UCB for a deal concerning the latter's Indian operations, citing a source with direct knowledge of the matter.
($1 = 62.3150 rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app